There are currently 1011 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
NCT04511013
Recruiting
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ipilimumab and nivolumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. This trial aims to find out which approach... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Conditions: Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Register for Updates
Specimen Collection From Pregnant Women at Increased Risk for Fetal Aneuploidy
NCT01429389
Recruiting
The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.
Gender:
Female
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: University of Alabama Birmingham, Birmingham, Alabama
Conditions: Down Syndrome, Fetal Aneuploidy
Register for Updates
NTX-301 in MDS/AML
NCT04167917
Recruiting
NTX-301 is a DNMT1 inhibitor. The drug is an oral drug with preclinical data that has shown preclinical anti-leukemic efficacy. This is the first clinical trial using NTX-301 in patients with myeloid malignancies.
Gender:
Male
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Register for Updates
Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain
NCT05037123
Recruiting
The study utilizes a 3-arm placebo-controlled RCT to study the effectiveness of ketamine in reducing chronic post-mastectomy pain. Participants randomized to the first arm will receive a 0.35 mg/kg dose after induction, followed by a 0.25 mg/kg/hr infusion during surgery (up to a maximum of 6 hours) and continued for 2 hours postoperatively. Participants in the second arm will receive a single dose of 0.6 mg/kg of ketamine in the post-anesthesia care unit, and the final group will serve as the c... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Chronic Postsurgical Pain
Register for Updates
Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
NCT03286556
Recruiting
Acute exacerbations (AE) are a dreaded manifestation of idiopathic pulmonary fibrosis (IPF) that presents with rapidly worsening respiratory function over days to weeks. AE account for about 1/2 the deaths in IPF patients, and are refractory to all medical therapies attempted to date. Considerable preliminary data shows pathological B-cell abnormalities and autoantibodies are present in AE-IPF and associated with disease severity. The experimental therapy here (therapeutic plasma exchange plus... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
08/04/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Idiopathic Pulmonary Fibrosis, Acute Fatal Form
Register for Updates
Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor
NCT04954664
Recruiting
This study will compare two techniques to achieve increase in ridge dimensions as a preparation for dental implants using a resorbable barrier membrane and bone particulate allogenic graft hydrated with saline or a growth factor called Recombinant Human Platelet-Derived Growth Factor (rhPDGF).
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
08/04/2023
Locations: Unversity of Alabama at Birmingham, School of Dentistry, Birmingham, Alabama
Conditions: Dental Implant, Bone Loss
Register for Updates
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
NCT03403686
Recruiting
Results from large clinical trials demonstrate a strong association between lipid abnormalities and progression of the most common microvascular complication, diabetic retinopathy (DR). We found that activation of a master regulator of cholesterol metabolism, the nuclear hormone receptors liver X receptors (LXRα/LXRβ), prevents DR in rodent models. In this application, we seek to understand the mechanisms responsible for the beneficial effects of LXR agonists on retina and on bone marrow (BM) to... Read More
Gender:
All
Ages:
Between 21 years and 98 years
Trial Updated:
08/04/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Diabetic Retinopathy
Register for Updates
An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)
NCT05025332
Recruiting
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Pitt Hopkins Syndrome.
Gender:
All
Ages:
Between 3 years and 17 years
Trial Updated:
08/03/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Pitt Hopkins Syndrome
Register for Updates
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
NCT05806164
Recruiting
The goal of this clinical trial is to compare treatment outcomes between an oral medication (beta agonist) versus onabotulinumtoxinA injections in women with urgency urinary incontinence (UUI). Participants will be randomly selected to receive one of the two treatments. The primary outcome measure will be at 3 months, and women will be followed for a total of 12 months. Based on patient expert input, there are 2 primary outcomes: Treatment satisfaction and urinary symptom severity.
Gender:
Female
Ages:
18 years and above
Trial Updated:
08/01/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Urgency Urinary Incontinence
Register for Updates
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
NCT03767348
Recruiting
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/01/2023
Locations: University of Birmingham Alabama, Birmingham, Alabama
Conditions: Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/30/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Breast Cancer
Register for Updates
Cognitive Remediation Intervention to Prepare for Transition of Care
NCT05336201
Recruiting
Randomized Controlled Trial (RTC) testing the efficacy of a telehealth adaptation of the Cognitive-Remediation of Executive and Adaptive Deficits in Youth (C-READY) intervention to prepare adolescents with sickle cell disease for transition of care.
Gender:
All
Ages:
Between 10 years and 18 years
Trial Updated:
07/28/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Sickle Cell Disease, Cognitive Impairment, Adolescent Behavior, Self Efficacy, Health-Related Behavior, Coping Skills
Register for Updates